| 000 | 01883 a2200541 4500 | ||
|---|---|---|---|
| 005 | 20250515022505.0 | ||
| 264 | 0 | _c20060418 | |
| 008 | 200604s 0 0 eng d | ||
| 022 | _a1537-453X | ||
| 024 | 7 |
_a10.1097/01.coc.0000203753.74851.d5 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aCuline, Stéphane | |
| 245 | 0 | 0 |
_aSubcutaneous interleukin-2 and interferon-alpha in metastatic renal cell carcinoma: results of a French regional experience in Languedoc. _h[electronic resource] |
| 260 |
_bAmerican journal of clinical oncology _cApr 2006 |
||
| 300 |
_a148-52 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Journal Article; Multicenter Study | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAntineoplastic Combined Chemotherapy Protocols _xadverse effects |
| 650 | 0 | 4 |
_aCarcinoma, Renal Cell _xdrug therapy |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aFrance |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aImmunotherapy |
| 650 | 0 | 4 | _aInjections, Subcutaneous |
| 650 | 0 | 4 |
_aInterferon-alpha _xadministration & dosage |
| 650 | 0 | 4 |
_aInterleukin-2 _xadministration & dosage |
| 650 | 0 | 4 |
_aKidney Neoplasms _xdrug therapy |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aNeoplasm Metastasis |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aIborra, François | |
| 700 | 1 | _aMottet, Nicolas | |
| 700 | 1 | _aAvancès, Christophe | |
| 700 | 1 | _ade Graeve, Bertrand | |
| 700 | 1 | _aVolpé, Pascal | |
| 700 | 1 | _aVignoud, Jacques | |
| 700 | 1 | _aBringer, Jean-Pierre | |
| 700 | 1 | _aMarroncle, Michel | |
| 700 | 1 | _aLe Pellec, Loïc | |
| 700 | 1 | _aAyuso, Didier | |
| 700 | 1 | _aJansen, Eric | |
| 700 | 1 | _aFaix, Antoine | |
| 700 | 1 | _aRebillard, Xavier | |
| 773 | 0 |
_tAmerican journal of clinical oncology _gvol. 29 _gno. 2 _gp. 148-52 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1097/01.coc.0000203753.74851.d5 _zAvailable from publisher's website |
| 999 |
_c16207048 _d16207048 |
||